Abstract 179P
Background
The elderly have numerous risk factors, such as comorbidities, undernutrition, and sarcopenia. Therefore, they require careful treatment indications and management in cancer treatment. Body composition and sarcopenia assessment have been performed in gastric cancer preoperative patients to improve perioperative outcomes since 2018, and we have provided nutritional/rehabilitative assessments and medical support to eligible patients with collaborative practice (CP).
Methods
Of 881 patients with gastrectomy between January 2011 and April 2023, aged 80 years or older were included in this study. We compared the short-term perioperative outcomes of patients with preoperative nutritional/rehabilitative assessments and support with CP (supportive (S) group) and without this assessment (non-supportive (NS) group).
Results
Sixty patients in the S group and 103 in the NS group. There were no differences in age, gender, performance status, Charlson comorbidity index, clinical Stage, or preoperative nutritional assessment, but the S group had a higher body mass index (median; S: 22.2 mg/m2 vs. NS: 21.5 mg/m2, p=0.02) and higher ASA-PS (ASA-PS ≥3, S: 48.4 vs. NS: 24.8%, p=0.002). The S group had fewer total gastrectomies (S: 15.0% vs. NS: 29.1%, p=0.037) and more robotic/laparoscopic approaches (S: 75.0% vs. NS: 30.1%, p<0.001). There was no difference in operative time but less blood loss in the S group (S: 50ml vs. NS: 230ml, p<0.001). Overall complications were lower in the S group (S: 20.0% vs. NS: 36.9%, p=0.021), but there was no difference in Clavien-Dindo ≥3 or higher complications (S: 6.7% vs. NS: 12.6%, p=0.21). In particular, the S group had fewer surgical site infections (S: 6.7% vs. NS: 17.5%, p=0.041) and pneumonia (S: 3.3% vs. NS: 15.5%, p=0.009). Postoperative hospital stay was shorter in the S group (S: 11 days vs. NS: 16 days, p<0.001).
Conclusions
Our results suggest that pre-operative nutritional/rehabilitative assessments and support in elderly gastric cancer patients led to fewer postoperative infectious complications and shorter hospital stays.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sakai City Medical Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract